首页365bet娱乐官网网址365bet国际娱乐城365bet体育在线官电子期刊下载专区广告合作征稿启事留言板
位置:首页 >> 电子期刊 >> 正文
不同制剂紫杉醇联合表柔比星治疗晚期乳腺癌的临床观察
作者:涂俊  杨娟  刘景丽  瞿广桥 
单位:武汉科技大学附属孝感医院肿瘤科  湖北 孝感 432000 
关键词:乳腺肿瘤/药物疗法 表柔比星/投药和剂量 表柔比星/治疗应用 药物疗法 联合 紫杉酚/投药和剂量 紫杉酚/类似物和衍生物 血清白蛋白 双盲法 治疗结果 
DOI:R737.9;R730.53
出版年,卷(期):页码:2017,32(2):168-172
摘要:

目的 探讨紫杉醇或白蛋白结合型紫杉醇联合表柔比星治疗晚期乳腺癌的临床疗效及不良反应。方法 选取62例晚期乳腺癌患者,按照随机对照双盲的原则将其分为治疗组和对照组各31例,其中治疗组采用白蛋白结合型紫杉醇(260 mg/m2)联合表柔比星(75 mg/m2)治疗,对照组采用紫杉醇(175 mg/m2)联合表柔比星(75 mg/m2)治疗。治疗2个周期后,观察比较两组患者的临床疗效及不良反应发生情况。结果 治疗组的治疗总有效率93.5%(29/31)高于对照组的71.0%(22/31),差异具有统计学意义(χ2=5.420,P=0.020)。两组不良反应发生率比较差异无统计学意义(P > 0.05)。结论 与紫杉醇联合多柔比星比较,白蛋白结合型紫杉醇联合表柔比星治疗晚期乳腺癌疗效好且不良反应可耐受。

Objective To investigate the clinical efficacy and toxicity of paclitaxel or albumin-bound paclitaxel combined with pirarubicin in treatment of advanced breast cancer. Methods Sixty-two patients with advanced breast cancer were assigned to study group and control group with 31 cases in each group. Patients in study group received albumin-bound paclitaxel(260 mg/m2) combined365bet娱乐官网网址 with pirarubicin(75 mg/m2),and those in control group received paclitaxel(175 mg/m2) combined with pirarubicin(75 mg/m2).The clinical efficacy and adverse reactions of the two groups were observed and compared after 2 cycles of chemotherapy. Results The total effective rate of study group was 93.5%(29/31),which was significantly higher than that of control group (71.0%, 22/31; χ2=5.42,P=0.020). No statistically significant difference was observed in the occurrence of adverse reactions between two groups(P > 0.05). Conclusion Albumin-bound paclitaxel has a better clinical effect than paclitaxel when combined with pirarubicin in treating advanced breast cancer, and the adverse reactions are tolerable in both protocols.

文章下载】【加入收藏

浙ICP备18004413号

技术服务qq:1507079184(投稿系统问题可找我)

编辑部地址:浙江省杭州市上城区解放路88号(浙医二院内)

电话:0571-87783654 邮编:310009 E-mail:shyzhl@zju.edu.cn

期刊介绍 使用帮助 | 365bet体育在线官 | 留言板